





Q2 FY 2018 Earnings Call  
Financial Results & Operational Highlights

# FINANCIAL RESULTS, Q2 FY 2018


### Revenue (\$M) & Growth Rate




### Cash (\$M)



### Gross Margin %




### Operating Margin %




# U.S. UTILIZATION MIX, Q2 FY 2018

Revenue by Impella Device




Utilization by Indication\*



Abiomed Revenue Growth:  
29%

U.S. Patient Growth:  
33%

U.S. Hospital Site Penetration



\* Protected PCI patients are elective and urgent PCI patients. Emergent includes AMI cardiogenic shock, post-surgery shock and other shock.

# ABIOMED FY 2018 GUIDANCE, AS OF OCTOBER 26, 2017

Abiomed FY'18 Initial Guidance
<b>Revenue</b> \$555 - \$575 ; 25 - 29%
<b>Operating Margin %</b> 22 - 24%

Abiomed FY'18 Post-Q2 Increased Guidance
<b>Revenue</b> <b>\$565 - \$575 ; 27 - 29%</b>
<b>Operating Margin %</b> <b>23 - 25%</b>

\* The Company initially increased the lower end of fiscal year 2018 revenue guidance to \$560 – 575M after reporting Q1 FY'18 financial results.